Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Janet Woodcock-Mitchell
Increased Plasminogen Activator Inhibitor Type 1 in Coronary Artery Atherectomy Specimens From Type 2 Diabetic Compared With Nondiabetic Patients : A Potential Factor Predisposing to Thrombosis and Its Persistence
Circulation
Cardiovascular Medicine
Physiology
Cardiology
Related publications
Comparison of Plasminogen Activator Inhibitor-1, Tissue Type Plasminogen Activator Antigen, Fibrinogen, and D-Dimer Levels in Various Age Decades in Patients With Type 2 Diabetes Mellitus and Stable Coronary Artery Disease (From the BARI 2D Trial)
American Journal of Cardiology
Cardiovascular Medicine
Cardiology
Thrombin and Plasmin Generation in Patients With Plasminogen or Plasminogen Activator Inhibitor Type 1 Deficiency
Haemophilia
Medicine
Genetics
Hematology
Accessibility of Receptor-Bound Urokinase to Type-1 Plasminogen Activator Inhibitor.
Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
Plasminogen Activator Inhibitor-1 Gene Polymorphism as a Risk Factor for Vascular Complications in Type 2 Diabetes Mellitus
Egyptian Journal of Medical Human Genetics
Genetics
Prognostic Value of Tissue-Type Plasminogen Activator (tPA) and Its Complex With the Type-1 Inhibitor (PAI-1) in Breast Cancer
British Journal of Cancer
Cancer Research
Oncology
Antidiabetic PPARgamma-Activator Rosiglitazone Reduces MMP-9 Serum Levels in Type 2 Diabetic Patients With Coronary Artery Disease
Arteriosclerosis, Thrombosis, and Vascular Biology
Cardiovascular Medicine
Cardiology
Human Visceral Adipose Tissue and the Plasminogen Activator Inhibitor Type 1
International Journal of Obesity
Nutrition
Endocrinology
Dietetics
Medicine
Metabolism
Diabetes
Interaction of Single-Chain Urokinase and Plasminogen Activator Inhibitor Type 1
Journal of Biological Chemistry
Biochemistry
Cell Biology
Molecular Biology
Increased Plasminogen Activator Inhibitor-1, Decreased Tissue Factor Pathway Inhibitor, and Unchanged Thrombin-Activatable Fibrinolysis Inhibitor Levels in Patients With Primary Hyperparathyroidism
European Journal of Endocrinology
Medicine
Endocrinology
Metabolism
Diabetes